Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:RGNXNASDAQ:RLAYNASDAQ:SLNNASDAQ:TYRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeRGNXREGENXBIO$9.71-1.5%$7.82$5.04▼$15.39$487.05M1.11880,673 shs645,180 shsRLAYRelay Therapeutics$2.91+2.1%$2.81$1.78▼$10.72$498.91M1.652.07 million shs939,082 shsSLNSilence Therapeutics$5.06+4.5%$3.44$1.97▼$22.71$151.45M1.2300,604 shs66,744 shsTYRATyra Biosciences$9.29-3.1%$9.43$6.42▼$29.60$493.21M1.17263,849 shs189,305 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceRGNXREGENXBIO-1.52%+9.22%+9.13%+33.56%-37.23%RLAYRelay Therapeutics+2.11%+3.56%-6.28%-25.77%-61.35%SLNSilence Therapeutics+4.55%+15.79%+52.41%+5.64%-78.21%TYRATyra Biosciences-3.13%-7.01%-7.29%-29.46%-47.48%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationRGNXREGENXBIO4.1773 of 5 stars3.42.00.04.62.53.30.6RLAYRelay Therapeutics3.1808 of 5 stars4.41.00.00.03.52.50.6SLNSilence Therapeutics3.4578 of 5 stars4.44.00.00.02.81.70.6TYRATyra Biosciences1.656 of 5 stars3.50.00.00.02.92.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceRGNXREGENXBIO 2.83Moderate Buy$31.63225.70% UpsideRLAYRelay Therapeutics 2.83Moderate Buy$17.67507.10% UpsideSLNSilence Therapeutics 2.71Moderate Buy$33.83568.64% UpsideTYRATyra Biosciences 3.00Buy$30.83231.90% UpsideCurrent Analyst Ratings BreakdownLatest SLN, TYRA, RLAY, and RGNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025TYRATyra BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$33.005/9/2025SLNSilence TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$4.00 ➝ $3.005/9/2025SLNSilence TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$45.00 ➝ $25.005/9/2025SLNSilence TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$55.00 ➝ $35.005/7/2025RLAYRelay TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $10.004/17/2025RGNXREGENXBIOThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$14.00 ➝ $12.004/17/2025RLAYRelay TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight$4.003/31/2025TYRATyra BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/28/2025TYRATyra BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$30.003/20/2025RGNXREGENXBIOChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$52.00 ➝ $52.003/18/2025RGNXREGENXBIOLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$24.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookRGNXREGENXBIO$156.72M3.11N/AN/A$7.09 per share1.37RLAYRelay Therapeutics$7.68M64.97N/AN/A$5.90 per share0.49SLNSilence Therapeutics$27.70M5.47N/AN/A$0.71 per share7.13TYRATyra BiosciencesN/AN/AN/AN/A$4.74 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateRGNXREGENXBIO-$263.49M-$3.11N/AN/AN/A-283.19%-70.65%-41.68%8/7/2025 (Estimated)RLAYRelay Therapeutics-$341.97M-$2.23N/AN/AN/AN/A-45.75%-40.75%8/5/2025 (Estimated)SLNSilence Therapeutics-$53.82M-$1.50N/AN/AN/A-342.00%-62.81%-33.89%N/ATYRATyra Biosciences-$69.13M-$1.63N/AN/AN/AN/A-24.56%-23.31%8/6/2025 (Estimated)Latest SLN, TYRA, RLAY, and RGNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025RGNXREGENXBIO$0.41$0.12-$0.29$0.12$105.35 million$89.01 million5/8/2025Q1 2025SLNSilence Therapeutics-$0.18-$0.60-$0.42-$0.60$3.58 million$0.14 million5/8/2025Q1 2025TYRATyra Biosciences-$0.49-$0.47+$0.02-$0.47N/AN/A5/5/2025Q1 2025RLAYRelay Therapeutics-$0.50-$0.46+$0.04-$0.46$0.01 million$7.68 million3/27/2025Q4 2024TYRATyra Biosciences-$0.48-$0.43+$0.05-$0.43N/AN/A3/13/2025Q4 2024RGNXREGENXBIO-$1.27-$1.01+$0.26-$1.01$23.70 million$21.21 million2/26/2025Q4 2024RLAYRelay Therapeutics-$0.57-$0.45+$0.12-$0.45$5.53 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthRGNXREGENXBION/AN/AN/AN/AN/ARLAYRelay TherapeuticsN/AN/AN/AN/AN/ASLNSilence TherapeuticsN/AN/AN/AN/AN/ATYRATyra BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioRGNXREGENXBION/A3.053.05RLAYRelay TherapeuticsN/A18.4218.42SLNSilence TherapeuticsN/A9.319.31TYRATyra BiosciencesN/A29.5529.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipRGNXREGENXBIO88.08%RLAYRelay Therapeutics96.98%SLNSilence Therapeutics98.73%TYRATyra Biosciences84.14%Insider OwnershipCompanyInsider OwnershipRGNXREGENXBIO12.79%RLAYRelay Therapeutics4.87%SLNSilence Therapeutics2.95%TYRATyra Biosciences15.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableRGNXREGENXBIO37050.16 million43.04 millionOptionableRLAYRelay Therapeutics330171.45 million160.15 millionOptionableSLNSilence Therapeutics10029.93 millionN/ANot OptionableTYRATyra Biosciences2053.09 million42.81 millionOptionableSLN, TYRA, RLAY, and RGNX HeadlinesRecent News About These CompaniesTyra Biosciences (NASDAQ:TYRA) Now Covered by Piper SandlerMay 23 at 10:11 AM | marketbeat.comHC Wainwright Has Optimistic Outlook of TYRA FY2025 EarningsMay 23 at 8:29 AM | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Coverage Initiated at Piper SandlerMay 23 at 1:27 AM | americanbankingnews.comEquities Analysts Offer Predictions for TYRA FY2026 EarningsMay 22 at 7:40 AM | marketbeat.comFY2025 EPS Forecast for Tyra Biosciences Boosted by AnalystMay 22 at 1:51 AM | americanbankingnews.comVestal Point Capital LP Makes New Investment in Tyra Biosciences, Inc. (NASDAQ:TYRA)May 21 at 8:14 AM | marketbeat.comDimensional Fund Advisors LP Increases Stock Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)May 19, 2025 | marketbeat.comJanus Henderson Group PLC Has $24.29 Million Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)May 18, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Purchases Shares of 244,245 Tyra Biosciences, Inc. (NASDAQ:TYRA)May 17, 2025 | marketbeat.comTyra Biosciences, Inc. (NASDAQ:TYRA) Shares Acquired by Orbimed Advisors LLCMay 15, 2025 | marketbeat.comCubist Systematic Strategies LLC Takes $1.53 Million Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)May 15, 2025 | marketbeat.comTyra Biosciences, Inc. (NASDAQ:TYRA) Receives $30.83 Average PT from BrokeragesMay 15, 2025 | americanbankingnews.comTyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Rating of "Buy" by BrokeragesMay 13, 2025 | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Issues Quarterly Earnings Results, Beats Expectations By $0.02 EPSMay 12, 2025 | marketbeat.comTyra Biosciences to Participate at Upcoming Investor ConferencesMay 12, 2025 | prnewswire.comFarallon Capital Management LLC Invests $13.91 Million in Tyra Biosciences, Inc. (NASDAQ:TYRA)May 11, 2025 | marketbeat.comOne Tyra Biosciences Insider Raised Stake By 284% In Previous YearMay 9, 2025 | finance.yahoo.com54,783 Shares in Tyra Biosciences, Inc. (NASDAQ:TYRA) Acquired by Raymond James Financial Inc.May 9, 2025 | marketbeat.comTyra Biosciences Reports First Quarter 2025 Financial Results and HighlightsMay 8, 2025 | prnewswire.comWhy Tyra Biosciences, Inc.’s (TYRA) Stock Is Down 5.48%May 6, 2025 | aaii.comTyra Biosciences, Inc. (NASDAQ:TYRA) Shares Sold by BVF Inc. ILMay 6, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLN, TYRA, RLAY, and RGNX Company DescriptionsREGENXBIO NASDAQ:RGNX$9.71 -0.15 (-1.52%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$9.91 +0.20 (+2.05%) As of 05/23/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.Relay Therapeutics NASDAQ:RLAY$2.91 +0.06 (+2.11%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.90 -0.01 (-0.17%) As of 05/23/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Silence Therapeutics NASDAQ:SLN$5.06 +0.22 (+4.55%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$5.07 +0.01 (+0.28%) As of 05/23/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.Tyra Biosciences NASDAQ:TYRA$9.29 -0.30 (-3.13%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$9.30 +0.01 (+0.05%) As of 05/23/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
